The Potential Clinical and Economic Impact of the Next-Generation COVID-19 mRNA-1283 Vaccine in Canada
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
With continued high disease burden observed in vulnerable groups and fiscal responsibility shifting to Canada’s jurisdictions, assessing the economic value of COVID-19 vaccines is critical for optimizing COVID-19 prevention. This study estimated the public health impact and economically justifiable price (EJP) of Moderna’s next-generation COVID-19 vaccine (mRNA-1283) versus no vaccination in Canada, and relative to currently authorized COVID-19 vaccines (mRNA-1273; BNT-162b2).
Methods
The target population included individuals aged ≥65 years and 12-64 years at high-risk of severe COVID-19 outcomes, consistent with 2025/2026 national guidelines. Analyses were conducted using a static decision-analytic model (1-year horizon) from a publicly funded healthcare payer perspective. Vaccine efficacy against infection and hospitalization for mRNA-1283 versus no 2024/2025 vaccination was based on mRNA-1283’s pivotal trial and mRNA-1273 real-world data. Clinical outcomes included symptomatic infections, hospitalizations, deaths, and number needed to vaccinate (NNV); economic outcomes included total costs, quality-adjusted life-years (QALY), and EJP at a $50,000/QALY willingness-to-pay threshold. Sensitivity analyses were performed.
Results
Compared to no vaccine, annual vaccination with mRNA-1283 prevented 288,912 symptomatic infections (NNV=15), 11,710 hospitalizations (NNV=364), and 2,194 deaths (NNV=1,944). The EJP for mRNA-1283 was $325 ($230-$771 in scenario analyses). Semi-annual dosing for those ≥65 years or ≥80 years averted additional hospitalizations and deaths compared to annual vaccination. mRNA-1283 prevented an additional 2,873-3,689 hospitalizations and 537-690 deaths compared to currently authorized vaccines. EJPs for mRNA-1283 were $78 and $103 when compared to mRNA-1273 and BNT162b2, respectively.
Interpretation
mRNA-1283 could reduce the COVID-19 clinical burden and provide economic value for the NACI-recommended population, exceeding current COVID-19 mRNA vaccines.
